London, UK (March 16-17, 2020)
SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020.
AI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR, AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
The presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning, neural networks and natural language processing. However, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms.
BENEFITS OF ATTENDING:
Join us at SMi’s inaugural AI in Drug Discovery 2020 Conference and explore the latest AI-enabled approaches for lead compound screening, multi parameter optimization, disease modelling, drug synthesis and design.
To register please visit: www.AI-indrugdiscovery.com/gate2wl
PLUS, one interactive half-day post-conference workshop
Practical application of predictive properties in drug design, Workshop Leader: Robert Young, Blue Burgundy Ltd.
Early-Bird Rates
BOOK BY 31ST JANUARY AND SAVE ?100
Gate2Biotech - Biotechnologický portál - Vše o biotechnologiích na jednom místě.
ISSN 1802-2685
Tvorba webových stránek: CREOS CZ
© 2006 - 2024 Jihočeská agentura pro podporu inovačního podnikání o.p.s.
Zajímavé články s biotechnologickým obsahem:
Zaměstnánà - poptávky - Možnost zdarma publikovat poptávaná zaměstnánà pro firmy a organizace
Věda - Dějiny vědy, historie vědy na Wikipedii
Levné nanočástice z rýžových otrub bojujàs nádory
Průlomová léčba, která regeneruje synapse při ALS, postupuje v klinických testech